Strongbridge Biopharma (NASDAQ:SBBP) was downgraded by investment analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued on Wednesday.
A number of other research firms have also issued reports on SBBP. Zacks Investment Research lowered shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday, January 17th. Cantor Fitzgerald set a $14.00 target price on shares of Strongbridge Biopharma and gave the company a “buy” rating in a research note on Wednesday, January 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Strongbridge Biopharma in a research note on Thursday, January 18th. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $12.81.
NASDAQ:SBBP opened at $8.30 on Wednesday. Strongbridge Biopharma has a 1 year low of $3.50 and a 1 year high of $9.25. The company has a debt-to-equity ratio of -3.17, a current ratio of 4.88 and a quick ratio of 4.84.
A number of large investors have recently bought and sold shares of SBBP. Paloma Partners Management Co acquired a new position in Strongbridge Biopharma in the 4th quarter valued at $152,000. Goldman Sachs Group Inc. bought a new stake in Strongbridge Biopharma in the 4th quarter valued at $272,000. California State Teachers Retirement System bought a new stake in Strongbridge Biopharma in the 2nd quarter valued at $277,000. Wells Fargo & Company MN boosted its holdings in Strongbridge Biopharma by 1,130.4% in the 4th quarter. Wells Fargo & Company MN now owns 44,640 shares of the biotechnology company’s stock valued at $324,000 after purchasing an additional 41,012 shares during the period. Finally, Deutsche Bank AG boosted its holdings in Strongbridge Biopharma by 185.0% in the 4th quarter. Deutsche Bank AG now owns 55,711 shares of the biotechnology company’s stock valued at $403,000 after purchasing an additional 36,160 shares during the period. Institutional investors and hedge funds own 57.63% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “BidaskClub Downgrades Strongbridge Biopharma (SBBP) to Buy” was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3334908/bidaskclub-downgrades-strongbridge-biopharma-sbbp-to-buy.html.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.